Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Pfizer Inc. announced today that the Japanese Ministry of Health, Labor and Welfare has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis who have had an inadequate response to existing therapies.

25 Mar 2013

$Immune system responds to fracture in similar way as to infection$

Immune system responds to fracture in similar way as to infection

Researchers at Charité - Universitätsmedizin Berlin have succeeded in demonstrating an association between delayed bone fracture healing and increased concentration of specific immune cells in the blood of the patient.

25 Mar 2013

Study shows certain T cells are stimulated to provide protective antibody responses with flu vaccines

Collaborating scientists from Nationwide Children's Hospital, Baylor Institute for Immunology Research, and Mount Sinai School of Medicine have identified an important mechanism for stimulating protective immune responses following seasonal influenza vaccinations.

25 Mar 2013

Botulism Antitoxin Heptavalent gets FDA approval for patients showing signs of botulism

The U.S. Food and Drug Administration announced today that it has approved Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin.

25 Mar 2013

HIV home tests: an interview with Dr Nitika Pant Pai, McGill University

30 years into the HIV epidemic, there is no vaccine in sight. Yet, even though there are fantastic and effective cheap and universally available drugs, and a treatment as prevention strategy is known to work, people do not wish to get tested for HIV! If everyone got tested, and treated, we could have brought the infection under control a long time ago!

21 Mar 2013

TSRI receives fund to develop new field test for Onchocerciasis

Philanthropist, businessman and community leader John Moores has given The Scripps Research Institute approximately $2 million to fund the development of a new field test for Onchocerciasis, or river blindness, a parasitic infection that affects tens of millions of people in Africa, Latin America and other tropical regions.

21 Mar 2013

Study: Novel strategy could lead to universal influenza vaccine that can provide long-lasting protection

Seasonal epidemics of influenza result in nearly 36,000 deaths annually in the United States, according to the Centers for Disease Control. Current vaccines against the influenza virus elicit an antibody response specific for proteins on the outside of the virus, specifically the hemagglutinin protein.

15 Mar 2013

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells.

14 Mar 2013

Immune system B cells play crucial role in defence of pathogens

Immune system B cells play a crucial role in the defence of pathogens; when they detect such an intruder, they produce antibodies that help to combat the enemy.

13 Mar 2013

Researchers determine way to predict and protect against new strains of flu virus

Researchers have determined a way to predict and protect against new strains of the flu virus, in the hope of improving immunity against the disease.

13 Mar 2013

Studies show protein semaphorin 3A helps detect acute kidney injury

A guidance cue that helps kidneys form may also be a red flag that they are in danger, researchers report.

13 Mar 2013

New, inexpensive nano-biosensor can detect Listeria monocytogenes in food

The foodborne bacteria Listeria monocytogenes sickens about 2,500 people in the U.S. each year and many more worldwide, killing about 25-30% of those infected. Listeriosis is caused by eating food contaminated with L. monocytogenes, and current methods for detecting the bacteria are costly and time consuming.

13 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.

11 Mar 2013

Inclacumab reduces damage to heart muscle during angioplasty

A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal.

11 Mar 2013

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (IBD).

8 Mar 2013

ADMA Biologics initiates enrollment in RI-002 Phase III study for PIDD

ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that the first patient enrolled in the pivotal Phase III clinical study of its RI-002 has been dosed.

7 Mar 2013

Omalizumab scratches the itch for urticaria patients

The monoclonal antibody omalizumab seems to be effective at relieving symptoms for patients with chronic idiopathic urticaria who have not responded to H1-antihistamine therapy, report US researchers.

5 Mar 2013

HIV might promote aging and disease progression in people with HCV, study results suggest

Infectious disease experts at Johns Hopkins have found that among people infected with the hepatitis C virus, co-infection with HIV, speeds damage and scarring of liver tissue by almost a decade.

5 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

Antibody News and Research

Further Reading

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Immune system responds to fracture in similar way as to infection

Study shows certain T cells are stimulated to provide protective antibody responses with flu vaccines

Botulism Antitoxin Heptavalent gets FDA approval for patients showing signs of botulism

HIV home tests: an interview with Dr Nitika Pant Pai, McGill University

TSRI receives fund to develop new field test for Onchocerciasis

Study: Novel strategy could lead to universal influenza vaccine that can provide long-lasting protection

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Immune system B cells play crucial role in defence of pathogens

Researchers determine way to predict and protect against new strains of flu virus

Studies show protein semaphorin 3A helps detect acute kidney injury

New, inexpensive nano-biosensor can detect Listeria monocytogenes in food

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Inclacumab reduces damage to heart muscle during angioplasty

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

ADMA Biologics initiates enrollment in RI-002 Phase III study for PIDD

Omalizumab scratches the itch for urticaria patients

HIV might promote aging and disease progression in people with HCV, study results suggest

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News